Current Clinical Trials for Children with Brain Tumor
UCSF Cancer Center • UCSF Brain Tumor Program
Department of Neurological Surgery & Brain Tumor Research Center

Questions about patients’ participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to malecm@neurosurg.ucsf.edu.

Pilot Study of Systemic and Intrathecal Chemotherapy followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors (PBTC 001)

Phase I/II Trial of ST1 571 in Children with Newly Diagnosed Poor Prognosis Brainstem Glioma and Recurrent Intracranial Malignant Glioma (PBTC 006)

Phase I Study of SU5416 in Pediatric Patients with Recurrent or Progressive Poor Prognosis Brain Tumors (PBTC 002)

Phase I Study of Intrathecal Spartaject Busulfan in Children with Neoplastic Meningitis (PBTC 004)

The following clinical trials for children with brain tumor are being performed in the UCSF Department of Pediatrics. More information about these trials can be found at www.som.ucsf.edu/ne/clinical_trials.htm. Questions about patients’ participation can be directed to Sara Koenig by calling 415-514-1489, or by email to koenigs@peds.ucsf.edu.

A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors (CCG 09716)

Phase II Study of Navelbine (Vinorelbine) in Children with Recurrent or Refractory Malignancies (CCG 09705)

Chemotherapy for Progressive Low-Grade Astrocytoma in Children Less Than Ten Years Old (CCG A9952)

Dose Escalation Study of 131I-Metaiodobenzylguanidine (MIBG) with Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma–A Phase I Study (NANT 99-01)

Treatment for Infants and Children with Intermediate Risk Neuroblastoma: A Phase III Intergroup CCG/POG Study (CCG A3961)

Randomized Treatment of Refractory Neuroblastoma with Topotecan Regimens, Following Deferoxamine (POG only) in an Investigational Window: A POG/ CCG Phase II Intergroup Study (CCG 9462)

Phase I Study of Concurrent Cereport and Carboplatin with Radiation Therapy for Children with Newly Diagnosed Brainstem Gliomas (ADVL 0012)

Phase I Study of Temozolomide and CCNU in Pediatric Patients with Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas (ADVL 0011)

Systemic Chemotherapy, Second-Look Surgery and Involved Field Radiation for Children ≥ 8 months and ≤ 36 months with Non-Metastatic Medulloblastoma (P9934)

Dose-Intensive Chemotherapy for Children Less than Ten Years of Age Newly Diagnosed with Malignant Brain Tumors

Brain Tumor Therapy at UCSF is a collaboration of UCSF’s Neurological Surgery, Neuro-Oncology, Radiation Oncology, Gamma-Knife, and Pediatric Programs, with the support of researchers in UCSF’s Brain Tumor Research Center (BTRC) and Michael Douglas Pediatric BTRC, and with close ties to organizations sponsoring support groups and other resources for patients with brain tumors.
Current Clinical Trials for Adults with Brain Tumor

Questions about patients' participation can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to malecm@neurosurg.ucsf.edu.

Phase I/II Study of the Safety and Tolerability of DTI-015 in Patients with Recurrent Glioblastoma Multiforme (00105)

Phase I Study to Assess the Histologic Effect and Safety of Pre-Operative and Post-Operative Infusions of IL13-PE38QQR Cytotoxin in Patients with Recurrent Resectable Supratentorial Malignant Glioma (01102)

A Phase II Study of Concurrent Temodar and Cis-Retinoic Acid with Radiation for Adult Patients with Newly Diagnosed Supratentorial Glioblastoma (BTRC 0101)

Phase I/II Trial of STI571 in Patients with Recurrent Malignant Gliomas (NABTC 9908)

Phase I/II Trial of CPT-11 and Temozolomide (Temodar) in Patients with Recurrent Malignant Glioma (NABTC 9907)

Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients with Recurrent Malignant Glioma or Metastatic Neoplasm to Brain (0004)

Phase I/II Trial of R115777 in Patients with Recurrent Malignant Glioma Phase II (NABTC 99-01)

Phase I/II Trial of SU5416 in Patients with Recurrent High Grade Astrocytomas or Mixed Gliomas (NABTC 99-02)

Phase II Evaluation of Fenretinide (NSC 374551) As a Single Agent in the Treatment of Adult Patients with Recurrent Malignant Glioma (NABTC 9905)

Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase III Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma (RTOG 98-02)

Single Center, Open Label Study to Evaluate the Safety of Hemoglobin-based Oxygen Carrier-201 (HBOC-201) with Carbogen Breathing During Irradiation in Newly Diagnosed Patients with Glioblastoma Multiforme (99107)

Phase II Study of Temozolomide (SCH 52365) in the Treatment of Adult Patients with Supratentorial Low Grade Glioma (99102)

Phase I Study of Gross Total Resection, Permanent Iodine-125 Brachytherapy, and Hyperfractionated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (98105)

Phase I/II Trial of Irinotecan (CPT-11) in Patients with Recurrent Malignant Glioma (NABTC 9801)

Phase I/II Study of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF) α and a Mutated Form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors

Phase I/II Trial of CCI-779 in Patients with Malignant Glioma (NABTC 0101)

Assessment of Needs for Complementary Medicine Program for Patients with Brain Tumors

Study of Distant Healing as an Adjunctive Intervention in Glioblastoma

Northern California Comprehensive Epilepsy Center Clinical Trial

Radiosurgical Treatment of Medial Temporal Lobe Epilepsy

For information, telephone Principal Investigator Nicholas Barbaro MD (415-353-7500 – Neurological Surgery) or Kenneth Laxer MD (415-476-6337 – Neurology), Director of the Northern California Comprehensive Epilepsy Center.